ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) announced today that it has entered into an exclusive worldwide license agreement with the University of Georgia Research Foundation (UGARF) for intellectual property covering a series of HIV integrase inhibitors and other antiviral compounds in exchange for an upfront license fee, future milestone payments and royalties on future net sales. Integrase inhibitors are an emerging class of anti-retroviral agents that block the insertion of viral DNA into the genome of the host cell, thereby stopping the virus from replicating. By inhibiting a different molecular target than currently marketed HIV drugs, integrase inhibitors have the potential to treat patients with resistant strains of HIV.
